TRVI
Trevi Therapeutics, Inc.
$13.50
+1.28%
$1.9B
No data for this timeframe.
Vol
Market Cap$1.9B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders7 funds
Inst. Value$201.6M
Inst. Activity2 buys / 4 sells
SEC Reports3
Press Releases5
Recent Activity
Jun 3, 2026
Insider
Heffernan Michael Thomas sold 35,000 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Colangelo Dominick sold 35,000 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Meeker David P sold 35,000 shares
Director @ $0.00 ($0.00)
May 20, 2026
short_volume
Short Volume: TRVI — 61.6% short (0.3M / 0.5M)
Short: 312,832 | Exempt: 0 | TRF Vol: 507,767 | Short Ratio: 61.6% | Off-exchange volume (dark pool
Apr 21, 2026
SEC
Trevi Therapeutics is holding its 2026 annual meeting where shareholders will vote on several proposals including electi
DEFA14A — Impact 3/10
Apr 20, 2026
Press
Trevi Therapeutics (TRVI) completed a public offering of 13.34 million shares at $13.00 per share, raising approximately
Impact 5/10
Apr 17, 2026
SEC
Trevi Therapeutics priced a $150.8 million follow-on offering of 11.6 million shares at $13.00 per share, just one day a
424B5 — Impact 7/10
Apr 17, 2026
SEC
Trevi Therapeutics priced a $150 million follow-on offering just one day after reporting earnings, raising concerns abou
8-K — Impact 7/10
Price Targets
$23.90
+75.9% upside
Strong Buy
Current $13.59
Low $20.00
Median $24.00
High $30.00
10 analysts
$20.00
$30.00
Analyst Ratings
6Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | Needham | REITERATE | Buy → Buy |
| May 6, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 6, 2026 | Needham | MAINTAIN | Buy → Buy |
| Apr 17, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | Jones Trading | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.11 ▼ -10.0% | $-0.12 — $-0.10 | -19% YoY | 9 |
| Next Q | $-0.13 ▼ -8.3% | $-0.15 — $-0.10 | -61% YoY | 9 |
| Current FY | $-0.47 ▼ -9.8% | $-0.52 — $-0.41 | -47% YoY | 9 |
| Next FY | $-0.56 ▲ +1.3% | $-0.72 — $-0.39 | -19% YoY | 9 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Trevi Therapeutics is holding its 2026 annual meeting where shareholders will vote on several proposals including electi
Apr 21, 2026
NEUTRAL
Press
5/10
Trevi Therapeutics (TRVI) completed a public offering of 13.34 million shares at $13.00 per share, raising approximately
Apr 20, 2026
BEARISH
424B5
7/10
Trevi Therapeutics priced a $150.8 million follow-on offering of 11.6 million shares at $13.00 per share, just one day a
Apr 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $81.4M | ADD |
| VANGUARD GROUP INC | $80.6M | ADD |
| BANK OF AMERICA CORP | $13.7M | TRIM |
| MORGAN STANLEY | $13.1M | NEAR_EXIT |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $10.5M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Heffernan Michael | A | $0.00 |
| Jun 3, 2026 | Colangelo Dominick | A | $0.00 |
| Jun 3, 2026 | Meeker David | A | $0.00 |
| Jun 3, 2026 | VANLENT ANNE | A | $0.00 |
| Jun 3, 2026 | Mathers Edward | A | $0.00 |
7 institutional holders with $201.6M total value (16,101,645 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, BANK. Net selling activity: 4 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 6,500,009 | $81.4M | 40.4% | ADD +97.0% |
| 2 | VANGUARD GROUP INC | 6,434,655 | $80.6M | 40.0% | ADD +38.5% |
| 3 | BANK OF AMERICA CORP /DE/ | 1,094,851 | $13.7M | 6.8% | TRIM -40.4% |
| 4 | MORGAN STANLEY | 1,050,296 | $13.1M | 6.5% | NEAR_EXIT -75.6% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 836,800 | $10.5M | 5.2% | DOUBLED +256.9% |
| 6 | WELLS FARGO & COMPANY/MN | 101,279 | $1.3M | 0.6% | ADD +81.9% |
| 7 | TWO SIGMA INVESTMENTS, LP | 83,755 | $1.0M | 0.5% | TRIM -30.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 3,299,891 | 6,500,009 | +97.0% | $81.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,836,839 | 1,094,851 | -40.4% | $13.7M | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 4,301,726 | 1,050,296 | -75.6% | $13.1M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 55,686 | 101,279 | +81.9% | $1.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 119,930 | 83,755 | -30.2% | $1.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 293,300 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,024,011 | 4,301,726 | +320.1% | $39.4M | 2025-Q3 |
| FMR LLC | DOUBLED | 368,529 | 3,299,891 | +795.4% | $30.2M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,097,497 | 1,836,839 | +67.4% | $16.8M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 225,935 | 806,331 | +256.9% | $7.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 489,300 | 293,300 | -40.1% | $2.7M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 41,171 | 55,686 | +35.3% | $509.5K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 3,838,032 | 5,316,691 | +38.5% | $29.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 131,765 | 1,097,497 | +732.9% | $6.0M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 494,567 | 1,024,011 | +107.1% | $5.6M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 88,900 | 489,300 | +450.4% | $2.7M | 2025-Q2 |
| FMR LLC | DOUBLED | 6,001 | 368,529 | +6041.1% | $2.0M | 2025-Q2 |
| UBS Group AG | DOUBLED | 93,033 | 354,225 | +280.8% | $1.9M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 190,869 | 494,567 | +159.1% | $3.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 1,299,876 | 136,200 | -89.5% | $856.7K | 2025-Q1 |
| UBS Group AG | DOUBLED | 45,515 | 93,033 | +104.4% | $585.2K | 2025-Q1 |
| FMR LLC | ADD | 4,360 | 6,001 | +37.6% | $37.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 54,981 | 1,299,876 | +2264.2% | $5.4M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 70,700 | 100,400 | +42.0% | $413.6K | 2024-Q4 |
| UBS Group AG | ADD | 27,862 | 45,515 | +63.4% | $187.5K | 2024-Q4 |
10 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Heffernan Michael Thomas | Director | A | 35,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Colangelo Dominick | Director | A | 35,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Meeker David P | Director | A | 35,000 | $0.00 | $0.00 |
| Jun 3, 2026 | VANLENT ANNE | Director | A | 35,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Mathers Edward T | Director | A | 35,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Cassella James V | Chief Development Officer | A | 215,000 | $0.00 | $0.00 |
| Feb 19, 2026 | SCIASCIA THOMAS | Chief Scientific Officer | A | 85,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Simon Farrell | Chief Commercial Officer | A | 160,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Galletta Christopher | See Remarks | A | 35,000 | $0.00 | $0.00 |
| Feb 19, 2026 | GOOD JENNIFER L | President & CEO | A | 675,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.7/10.
NEUTRAL
DEFA14A
3/10
Trevi Therapeutics is holding its 2026 annual meeting where shareholders will vote on several propos
Apr 21, 2026
BEARISH
424B5
7/10
Trevi Therapeutics priced a $150.8 million follow-on offering of 11.6 million shares at $13.00 per s
Apr 17, 2026
BEARISH
8-K
7/10
Trevi Therapeutics priced a $150 million follow-on offering just one day after reporting earnings, r
Apr 17, 2026
NEUTRAL
5/10
Trevi Therapeutics (TRVI) completed a public offering of 13.34 million shares at $13.00 per share, r
Apr 20, 2026
NEUTRAL
6/10
Trevi Therapeutics priced an underwritten public offering of 11,600,000 shares at $13.00 per share,
Apr 17, 2026
MIXED
6/10
Trevi Therapeutics reported fourth quarter and full-year 2025 financial results, highlighted by a re
Mar 17, 2026
NEUTRAL
3/10
Trevi Therapeutics announced an upcoming conference call to discuss its fourth quarter and full-year
Mar 10, 2026
BULLISH
7/10
Trevi Therapeutics announced positive feedback from its End-of-Phase 2 meeting with the FDA, confirm
Mar 9, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 6 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$23.90 mean target
+75.9% upside
Strong Buy (3.00)
$20.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $13.59 |
| Target Low | $20.00 |
| Target Mean | $23.90 |
| Target Median | $24.00 |
| Target High | $30.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.11 | $-0.12 | $-0.10 | -18.5% | -10.0% | 2↑ 1↓ | $0.0B | 0.0% | 9 |
| Next Q 2026-09-30 |
$-0.13 | $-0.15 | $-0.10 | -61.1% | -8.3% | 3↑ 1↓ | $0.0B | 0.0% | 9 |
| Current FY 2026-12-31 |
$-0.47 | $-0.52 | $-0.41 | -46.5% | -9.8% | 3↑ 1↓ | $0.0B | 0.0% | 9 |
| Next FY 2027-12-31 |
$-0.56 | $-0.72 | $-0.39 | -19.0% | +1.3% | 3↑ 0↓ | $0.0B | 0.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.107 | |
| 7d ago | $-0.102 | -0.005 |
| 30d ago | $-0.097 | -0.010 |
| 60d ago | $-0.098 | -0.009 |
| 90d ago | $-0.117 | +0.011 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | Needham | REITERATE | Buy | Buy |
| May 6, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 6, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | Jones Trading | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 18, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | Stifel | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
short_volume
Short Volume: TRVI — 61.6% short (0.3M / 0.5M)
Short: 312,832 | Exempt: 0 | TRF Vol: 507,767 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
TRVI Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
short_volume
Short Volume: TRVI — 63.8% short (0.5M / 0.7M)
Short: 463,058 | Exempt: 0 | TRF Vol: 726,331 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics to host conference call and webcast today, May 5, on 1Q 2026 financial results and business updates
Apr 29, 2026
short_volume
Short Volume: TRVI — 58.5% short (0.4M / 0.6M)
Short: 375,182 | Exempt: 0 | TRF Vol: 641,056 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Apr 23, 2026
other
Trevi Therapeutics to Participate in Upcoming May Events
<p>NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8FOQ492THrn4-uNBh_CjXNYq2auWoL5MQ6OektFA
Apr 23, 2026
short_interest
FTD: TRVI — 81,694 shares ($1.2M) failed to deliver
Settlement: 20260423, Price: $14.80, FTD Value: $1,209,071.2, TREVI THERAPEUTICS INC COM
Apr 21, 2026
short_volume
Short Volume: TRVI — 58.0% short (0.5M / 0.8M)
Short: 492,524 | Exempt: 0 | TRF Vol: 849,600 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_interest
FTD: TRVI — 35,914 shares ($0.6M) failed to deliver
Settlement: 20260421, Price: $15.40, FTD Value: $553,075.6, TREVI THERAPEUTICS INC COM
Apr 20, 2026
offering
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
<p>NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developi
Apr 17, 2026
offering
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
<p>NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developi
Apr 16, 2026
offering
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
<p>NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developi
Apr 7, 2026
short_volume
Short Volume: TRVI — 76.8% short (0.4M / 0.5M)
Short: 416,589 | Exempt: 0 | TRF Vol: 542,646 | Short Ratio: 76.8% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: TRVI — 79.8% short (0.6M / 0.7M)
Short: 582,578 | Exempt: 0 | TRF Vol: 730,169 | Short Ratio: 79.8% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_volume
Short Volume: TRVI — 55.1% short (0.3M / 0.5M)
Short: 289,519 | Exempt: 0 | TRF Vol: 525,443 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
Phase Phase 2 — COMPLETED